Latest & greatest articles for pravastatin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on pravastatin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on pravastatin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for pravastatin

21. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up.

Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. 11978335 2002 04 29 2002 05 08 2015 06 16 0140-6736 359 9315 2002 Apr 20 Lancet (London, England) Lancet Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. 1379-87 The Long-term Intervention with Pravastatin in Ischaemic (...) Disease (LIPID) study showed that pravastatin therapy over 6 years reduced mortality and cardiovascular events in patients with previous acute coronary syndromes and average cholesterol concentrations. We assessed the longer-term effects of initial treatment with pravastatin on further cardiovascular events and mortality over a total follow-up period of 8 years. In the main trial, 9014 patients with previous myocardial infarction or unstable angina and a baseline plasma cholesterol concentration

Lancet2002

22. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial.

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. 12457784 2002 11 29 2002 12 10 2015 06 16 0140-6736 360 9346 2002 Nov 23 Lancet (London, England) Lancet Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. 1623-30 Although statins reduce coronary and cerebrovascular morbidity and mortality in middle-aged individuals, their efficacy and safety in elderly people is not fully established (...) . Our aim was to test the benefits of pravastatin treatment in an elderly cohort of men and women with, or at high risk of developing, cardiovascular disease and stroke. We did a randomised controlled trial in which we assigned 5804 men (n=2804) and women (n=3000) aged 70-82 years with a history of, or risk factors for, vascular disease to pravastatin (40 mg per day; n=2891) or placebo (n=2913). Baseline cholesterol concentrations ranged from 4.0 mmol/L to 9.0 mmol/L. Follow-up was 3.2 years

Lancet2002

23. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). 12479764 2002 12 13 2002 12 24 2016 10 17 0098-7484 288 23 2002 Dec 18 JAMA JAMA Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT (...) ). 2998-3007 Studies have demonstrated that statins administered to individuals with risk factors for coronary heart disease (CHD) reduce CHD events. However, many of these studies were too small to assess all-cause mortality or outcomes in important subgroups. To determine whether pravastatin compared with usual care reduces all-cause mortality in older, moderately hypercholesterolemic, hypertensive participants with at least 1 additional CHD risk factor. Multicenter (513 primarily community-based

JAMA2002

24. Effect of pravastatin-to-simvastatin conversion on low-density-lipoprotein cholesterol

Effect of pravastatin-to-simvastatin conversion on low-density-lipoprotein cholesterol Effect of pravastatin-to-simvastatin conversion on low-density-lipoprotein cholesterol Effect of pravastatin-to-simvastatin conversion on low-density-lipoprotein cholesterol Ito M K, Lin J C, Morreale A P, Marcus D B, Shabetai R, Dresselhaus T R, Henry R R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief (...) summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of simvastatin to reduce low-density lipoprotein (LDL) cholesterol levels. Type of intervention Primary and secondary prevention. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients receiving pravastatin at a Veterans Affairs medical centre. Setting The setting

NHS Economic Evaluation Database.2001

25. Cerivastatin versus branded pravastatin in the treatment of primary hypercholesterolaemia in primary care practice in Canada: a one-year, open-label, randomized, comparative study of efficacy, safety, and cost-effectiveness

Cerivastatin versus branded pravastatin in the treatment of primary hypercholesterolaemia in primary care practice in Canada: a one-year, open-label, randomized, comparative study of efficacy, safety, and cost-effectiveness Cerivastatin versus branded pravastatin in the treatment of primary hypercholesterolaemia in primary care practice in Canada: a one-year, open-label, randomized, comparative study of efficacy, safety, and cost-effectiveness Cerivastatin versus branded pravastatin (...) and the conclusions drawn. Health technology Cerivastatin (third-generation statin) and branded pravastatin (first-generation statin) were evaluated for the treatment of primary hypercholesterolaemia: Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised adult patients with documented primary hypercholesterolaemia that did not respond adequately to dietary interventions. The patients were aged between 18 and 75 years. The patient's

NHS Economic Evaluation Database.2001

26. Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels

Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels Tsevat J, Kuntz K M, Orav E J, Weinstein M C, Sacks F M, Goldman L Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The health technology under investigation was pravastatin therapy (PT). This is an aggressive cholesterol-lowering strategy for the treatment of patients who have already experienced coronary heart disease and are at high risk of having ischaemic events. Type of intervention

NHS Economic Evaluation Database.2001

27. Low-density lipoprotein size, pravastatin treatment, and coronary events.

Low-density lipoprotein size, pravastatin treatment, and coronary events. 11572739 2001 09 26 2001 10 18 2016 10 17 0098-7484 286 12 2001 Sep 26 JAMA JAMA Low-density lipoprotein size, pravastatin treatment, and coronary events. 1468-74 Small low-density lipoprotein (LDL) particle size has been hypothesized to be a risk factor for coronary heart disease (CHD). Animal models link large LDL to atherosclerosis. However, the strong association between small LDL and other risk factors, particularly (...) triglyceride levels, impedes determining whether LDL size independently predicts CHD in humans. To examine whether LDL size is an independent predictor of recurrent coronary events in patients with known CHD, as opposed to a marker for other lipid abnormalities. Prospective, nested case-control study in the Cholesterol and Recurrent Events (CARE) trial, a randomized placebo-controlled trial of pravastatin conducted in 1989-1996. Survivors of myocardial infarction with typical LDL concentrations (416 cases

JAMA2001

28. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study.

Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. 11434828 2001 07 03 2001 07 26 2016 10 17 0098-7484 286 1 2001 Jul 04 JAMA JAMA Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. 64-70 Plasma levels of the inflammatory biomarker C-reactive protein (CRP) predict cardiovascular risk, and retrospective (...) studies suggest that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) may lower CRP in a manner largely independent of low-density lipoprotein cholesterol (LDL-C). However, prospective trial data directly evaluating this anti-inflammatory effect of statins are not available. To test the hypothesis that pravastatin has anti-inflammatory effects as evidenced by CRP reduction. Community-based, prospective, randomized, double-blind trial including 1702 men and women with no prior

JAMA2001

29. Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease.

Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease. 11229669 2001 03 02 2001 03 15 2015 06 16 0140-6736 357 9255 2001 Feb 17 Lancet (London, England) Lancet Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease. 509-12 Statins inhibit the (...) randomised controlled trial of these agents. 9014 patients (17% women, median age 62 years) with ischaemic heart disease were randomly assigned pravastatin 40 mg daily or placebo and followed up for a mean of 6.0 years. Fractures were ascertained from adverse-event reports. 101 patients in the placebo group were admitted to hospital for fracture compared with 107 in the pravastatin group (hazard ratio 1.05 [95% CI 0.80-1.37]). When patients with fractures not necessitating hospital admission were added

Lancet2001

30. Pravastatin therapy and the risk of stroke.

Pravastatin therapy and the risk of stroke. 10922421 2000 08 03 2000 08 03 2013 11 21 0028-4793 343 5 2000 Aug 03 The New England journal of medicine N. Engl. J. Med. Pravastatin therapy and the risk of stroke. 317-26 Several epidemiologic studies have concluded that there is no relation between total cholesterol levels and the risk of stroke. In some studies that classified strokes according to cause, there was an association between increasing cholesterol levels and the risk of ischemic (...) stroke and a possible association between low cholesterol levels and the risk of hemorrhagic stroke. Recent reviews of trials of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors have suggested that these agents may reduce the risk of stroke. In a double-blind trial (the Long-Term Intervention with Pravastatin in Ischaemic Disease study), we compared the effects of pravastatin on mortality due to coronary heart disease (the primary end point) with the effects of placebo among 9014 patients

NEJM2000

31. Effects of pravastatin in 3260 patients with unstable angina: results from the LIPID study.

Effects of pravastatin in 3260 patients with unstable angina: results from the LIPID study. 11130382 2000 12 20 2001 01 11 2015 06 16 0140-6736 356 9245 2000 Dec 02 Lancet (London, England) Lancet Effects of pravastatin in 3260 patients with unstable angina: results from the LIPID study. 1871-5 The LIPID study is a major trial of secondary prevention of coronary-heart-disease events that includes hospital admission with unstable angina (as well as myocardial infarction) as a qualifying event (...) . In this substudy of LIPID, we compared subsequent cardiovascular risks and the effects of pravastatin in patients with previous unstable angina or previous myocardial infarction. 3260 patients diagnosed with unstable angina and 5754 with acute myocardial infarction 3-36 months previously were randomly assigned 40 mg pravastatin daily or placebo over a mean of 6.0 years. The risk reduction of a range of cardiovascular events was estimated by means of the hazard ratio in Cox's proportional hazards model. Among

Lancet2000

32. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group.

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. 9841303 1998 11 05 1998 11 05 2013 11 21 0028-4793 339 19 1998 Nov 05 The New England journal of medicine N. Engl. J. Med. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial (...) cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. 1349-57 In patients with coronary heart disease and a broad range of cholesterol levels, cholesterol-lowering therapy reduces the risk of coronary events, but the effects on mortality from coronary heart disease and overall mortality have remained uncertain. In a double-blind, randomized trial, we compared the effects of pravastatin (40 mg daily) with those of a placebo over a mean follow-up period

NEJM1998

33. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin

The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin Caro J, Klittich W, McGuire A, Ford I, Norrie J, Pettitt D, McMurray J, Shepherd J Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Use of pravastatin in addition to the usual lipid-lowering dietary advice in the prevention of cardiovascular disease. Type of intervention Primary prevention. Economic study type Cost-effectiveness analysis. Study population Scottish men aged 45-64 years

NHS Economic Evaluation Database.1997

34. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin.

The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin. 9437275 1998 02 04 1998 02 04 2013 11 21 0959-8138 315 7122 1997 Dec 13 BMJ (Clinical research ed.) BMJ The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin. 1577-82 To estimate the economic efficiency of using pravastatin to prevent the transition from health to cardiovascular disease in men with hypercholesterolaemia (...) of Scotland coronary prevention study. Cost consequences, the number of transitions from health to cardiovascular disease prevented, the number needed to start treatment, and cost per life year gained. If 10,000 of these men started taking pravastatin, 318 of them would not make the transition from health to cardiovascular disease (number needed to treat, 31.4), at a net discounted cost of 20m Pounds over 5 years. These benefits imply an undiscounted gain of 2,460 years of life, and thus 8121 Pounds per

BMJ1997 Full Text: Link to full Text with Trip Pro

35. Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease

Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease Ashraf T, Hay J W, Pitt B, Wittels E, Crouse J, Davidson M, Furberg C D, Radican L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Cholesterol lowering using pravastatin in people with Coronary Artery Disease (CAD). Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study population Male patients (n=445, mean age of 60 years) with CAD and moderately elevated serum low-density lipoprotein cholesterol. Setting The practice setting

NHS Economic Evaluation Database.1996

36. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. 8801446 1996 10 03 1996 10 03 2013 11 21 0028-4793 335 14 1996 Oct 03 The New England journal of medicine N. Engl. J. Med. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. 1001-9 In patients with high (...) cholesterol levels, lowering the cholesterol level reduces the risk of coronary events, but the effect of lowering cholesterol levels in the majority of patients with coronary disease, who have average levels, is less clear. In a double-blind trial lasting five years we administered either 40 mg of pravastatin per day or placebo to 4159 patients (3583 men and 576 women) with myocardial infarction who had plasma total cholesterol levels below 240 mg per deciliter (mean, 209) and low-density lipoprotein

NEJM1996

37. Replacing lovastatin with pravastatin: effect on serum lipids and costs

Replacing lovastatin with pravastatin: effect on serum lipids and costs Replacing lovastatin with pravastatin: effect on serum lipids and costs Replacing lovastatin with pravastatin: effect on serum lipids and costs Korman L, Borysiuk L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability (...) of the study and the conclusions drawn. Health technology Pravastatin. Type of intervention Primary prevention. Economic study type Cost-effectiveness analysis. Study population Patients being treated with lovastatin, with an average age of 66 years. Setting Primary care. The economic study was carried out in Connecticut, USA. Dates to which data relate Costs mainly related to 1993 and were expressed in 1995 prices. Effectiveness data were collected up until October 1993. Source of effectiveness data

NHS Economic Evaluation Database.1995

38. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. 7566020 1995 11 21 1995 11 21 2013 11 21 0028-4793 333 20 1995 Nov 16 The New England journal of medicine N. Engl. J. Med. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. 1301-7 Lowering the blood cholesterol level may reduce the risk of coronary (...) heart disease. This double-blind study was designed to determine whether the administration of pravastatin to men with hypercholesterolemia and no history of myocardial infarction reduced the combined incidence of nonfatal myocardial infarction and death from coronary heart disease. We randomly assigned 6595 men, 45 to 64 years of age, with a mean (+/- SD) plasma cholesterol level of 272 +/- 23 mg per deciliter (7.0 +/- 0.6 mmol per liter) to receive pravastatin (40 mg each evening) or placebo. The average follow-up

NEJM1995

39. Effect of pravastatin on outcomes after cardiac transplantation.

Effect of pravastatin on outcomes after cardiac transplantation. 7637722 1995 09 14 1995 09 14 2016 11 23 0028-4793 333 10 1995 Sep 07 The New England journal of medicine N. Engl. J. Med. Effect of pravastatin on outcomes after cardiac transplantation. 621-7 Hypercholesterolemia is common after cardiac transplantation and may contribute to the development of coronary vasculopathy. Pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, has been shown to be effective (...) and safe in lowering cholesterol levels after cardiac transplantation. Cell-culture studies using inhibitors of HMG-CoA reductase have suggested an immunosuppressive effect. Early after transplantation, we randomly assigned consecutive patients to receive either pravastatin (47 patients) or no HMG-CoA reductase inhibitor (50 patients). Twelve months after transplantation, the pravastatin group had lower mean (+/- SD) cholesterol levels than the control group (193 +/- 36 vs. 248 +/- 49 mg per deciliter

NEJM1995

40. Treatment of familial hypercholesterolaemia. United Kingdom lipid clinics study of pravastatin and cholestyramine.

Treatment of familial hypercholesterolaemia. United Kingdom lipid clinics study of pravastatin and cholestyramine. 1611329 1992 07 28 1992 07 28 2013 11 21 0959-8138 304 6838 1992 May 23 BMJ (Clinical research ed.) BMJ Treatment of familial hypercholesterolaemia. United Kingdom lipid clinics study of pravastatin and cholestyramine. 1335-8 To compare the efficacy and safety of cholestyramine, an anion exchange resin, and pravastatin, a new hydrophilic specific inhibitor of 3-hydroxy-3 (...) -methylglutaryl coenzyme A reductase, in the treatment of heterozygous familial hypercholesterolaemia. Double blind, double dummy, placebo controlled study with three parallel groups. Six specialist lipid clinics in the United Kingdom. 128 patients aged 18-70 with heterozygous familial hypercholesterolaemia diagnosed on strict biochemical and clinical findings. Total plasma cholesterol, triglyceride, and lipoprotein subfractions and biochemical and haematological safety parameters. Pravastatin (40 mg/day) led

BMJ1992 Full Text: Link to full Text with Trip Pro